Jaguar Health expands crofelemer compassionate use to EU infant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
July 22, 2026 9:01 AM EDTJaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID
SAN FRANCISCO, CA / ACCESS Newswire / July 22, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer... More
